Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer

British Journal of Cancer

Volumn 104, Issue 10, 2011, Pages 1611-1618

  Voss, M A ^a,b   Gordon, N ^b   Maloney, S ^c   Ganesan, R ^d   Ludeman, L ^a   McCarthy, K ^a   Gornall, R ^a   Schaller, G ^e   Wei, W ^b   Berditchevski, F ^b   Sundar, S ^b  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c University of Birmingham   (United Kingdom)

^d BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e Breast Care Institute (BCI)   (Germany)

Author keywords

endometrial cancer; prognostic marker; tetraspanin CD151; type II

Indexed keywords

CD151 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; UVOMORULIN; VERY LATE ACTIVATION ANTIGEN 3; VERY LATE ACTIVATION ANTIGEN 6;

ADULT; AGE; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOSARCOMA; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM SARCOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; UTERUS CARCINOMA;

EID: 85027921190     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.80     Document Type: Article

References (46)

1. Ang J, Lijovic M, Ashman LK, Kan K, Frauman AG (2004) CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Cancer Epidemiol Biomarkers Prev 13: 1717-1721 (Pubitemid 39482947)
2. Bansal N, Yendluri V, Wenham RM (2009) The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16: 8-13
3. Berditchevski F, Chang S, Bodorova J, Hemler ME (1997) Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6. J Biol Chem 272: 29174-29180 (Pubitemid 27498208)
4. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17 (Pubitemid 13194678)
5. Bray F, Dos Santos Silva I, Moller H, Weiderpass E (2005) Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev 14: 1132-1142 (Pubitemid 40656458)
6. Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL, McCarty Jr KS (1986) Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46: 5419-5425 (Pubitemid 16008326)
7. Cancer Research UK (2010) Vol. 2010. http://info.cancerresearchuk.org/ cancerstats/types/uterus/
8. Carcangiu ML, Chambers JT (1992) Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 47: 298-305 (Pubitemid 23011408)
9. Carcangiu ML, Chambers JT (1995) Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol 14: 30-38
10. Chien CW, Lin SC, Lai YY, Lin BW, Lee JC, Tsai SJ (2008) Regulation of CD151 by hypoxia controls cell adhesion and metastasis in colorectal cancer. Clin Cancer Res 14: 8043-8051
11. Deniaud-Alexandre E, Chauveinc L, de la Rochefordiere A, Sastre X, Clough KB (2001) [Role of adjuvant therapy in uterine sarcoma: experience of the Curie Institute]. Cancer Radiother 5: 743-749 (Pubitemid 34016950)
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917
13. Giuntoli II RL, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, Gostout BS (2003) Retrospective review of 208 patients with leiomyo-sarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol 89: 460-469 (Pubitemid 36687793)
14. Hasegawa H, Nomura T, Kishimoto K, Yanagisawa K, Fujita S (1998) SFA-1/PETA-3 (CD151), a member of the transmembrane 4 superfamily, associates preferentially with alpha 5 beta 1 integrin and regulates adhesion of human T cell leukemia virus type 1-infected T cells to fibronectin. J Immunol 161: 3087-3095 (Pubitemid 28425736)
15. Hemler ME (2008) Targeting of tetraspanin proteins-potential benefits and strategies. Nat Rev Drug Discov 7: 747-758
16. Holcomb K, Delatorre R, Pedemonte B, McLeod C, Anderson L, Chambers J (2002) E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol 100: 1290-1295 (Pubitemid 35449197)
17. Humber C, Tierney J, Symonds P, Collingwood M, Kirwan J, Williams C, Green J (2005) Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev. Art. No. CD003915
18. Katz RL, Patel S, Sneige N, Fritsche Jr HA, Hortobagyi GN, Ames FC, Brooks T, Ordonez NG (1990) Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res Treat 15: 191-203 (Pubitemid 20369899)
19. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373: 125-136
20. Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL, Marks JR, Berchuck A (1996) p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 175: 1246-1252 (Pubitemid 26398986)
21. Lammerding J, Kazarov AR, Huang H, Lee RT, Hemler ME (2003) Tetraspanin CD151 regulates alpha6beta1 integrin adhesion strengthening. Proc Natl Acad Sci USA 100: 7616-7621 (Pubitemid 36760018)
22. Lax SF, Kurman RJ (1997) A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 81: 228-232
23. Levenback C, Burke TW, Silva E, Morris M, Gershenson DM, Kavanagh JJ, Wharton JT (1992) Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 46: 317-321
24. Livi L, Paiar F, Shah N, Blake P, Villanucci A, Amunni G, Barca R, Judson I, Lodge N, Meldolesi E, Simontacchi G, Piperno G, Galardi A, Scoccianti S, Biti GP, Harmer C (2003) Uterine sarcoma: twenty-seven years of experience. Int J Radiat Oncol Biol Phys 57: 1366-1373 (Pubitemid 37443978)
25. Maxwell GL, Risinger JI, Alvarez AA, Barrett JC, Berchuck A (2001) Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 97: 417-422 (Pubitemid 32184704)
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391 (Pubitemid 43080010)
27. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24: 2376-2385 (Pubitemid 46630670)
28. Novitskaya V, Romanska H, Dawoud M, Jones JL, Berditchevski F (2010) Tetraspanin CD151 regulates growth of mammary epithelial cells in three-dimensional extracellular matrix: implication for mammary ductal carcinoma in situ. Cancer Res 70: 4698-4708
29. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A (1998) PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 4: 3005-3010 (Pubitemid 29001474)
30. Rose PG (1996) Endometrial carcinoma. N Engl J Med 335: 640-649 (Pubitemid 26277956)
31. Sadej R, Romanska H, Baldwin G, Gkirtzimanaki K, Novitskaya V, Filer AD, Krcova Z, Kusinska R, Ehrmann J, Buckley CD, Kordek R, Potemski P, Eliopoulos AG, Lalaniel N, Berditchevski F (2009) CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res 7: 787-798
32. Sadej R, Romanska H, Kavanagh D, Baldwin G, Takahashi T, Kalia N, Berditchevski F (2010) Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res 70: 6059-6070
33. Sincock PM, Fitter S, Parton RG, Berndt MC, Gamble JR, Ashman LK (1999) PETA-3/CD151, a member of the transmembrane 4 superfamily, is localised to the plasma membrane and endocytic system of endothelial cells, associates with multiple integrins and modulates cell function. J Cell Sci 112(Pt 6): 833-844 (Pubitemid 29179316)
34. Singh P, Smith CL, Cheetham G, Dodd TJ, Davy ML (2008) Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. Int J Gynecol Cancer 18: 1344-1351
35. Stipp CS (2010) Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev Mol Med 12: e3
36. Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, Lentz SS, Sorosky J, Hsiu JG (2000) A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol 79: 147-153
37. Testa JE, Brooks PC, Lin JM, Quigley JP (1999) Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res 59: 3812-3820 (Pubitemid 29381891)
38. Tokuhara T, Hasegawa H, Hattori N, Ishida H, Taki T, Tachibana S, Sasaki S, Miyake M (2001) Clinical significance of CD151 gene expression in non-small cell lung cancer. Clin Cancer Res 7: 4109-4114 (Pubitemid 34044635)
39. Toyoshima M, Akahira J, Matsunaga G, Niikura H, Ito K, Yaegashi N, Tase T (2004) Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol 94: 774-778 (Pubitemid 39194474)
40. Weitmann HD, Kucera H, Knocke TH, Potter R (2002) Surgery and adjuvant radiation therapy of endometrial stromal sarcoma. Wien Klin Wochenschr 114: 44-49 (Pubitemid 34112657)
41. Wilder JL, Shajahan S, Khattar NH, Wilder DM, Yin J, Rushing RS, Beaven R, Kaetzel C, Ueland FR, van Nagell JR, Kryscio RJ, Lele SM (2004) Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study. Gynecol Oncol 92: 553-558 (Pubitemid 38183144)
42. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145 (Pubitemid 350003059)
43. Yanez-Mo M, Alfranca A, Cabanas C, Marazuela M, Tejedor R, Ursa MA, Ashman LK, de Landazuri MO, Sanchez-Madrid F (1998) Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions. J Cell Biol 141: 791-804 (Pubitemid 28217922)
44. Yauch RL, Berditchevski F, Harler MB, Reichner J, Hemler ME (1998) Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidyl-inositol 4-kinase, and may regulate cell migration. Mol Biol Cell 9: 2751-2765 (Pubitemid 28473659)
45. Zhang XA, Bontrager AL, Hemler ME (2001) Transmembrane-4 super-family proteins associate with activated protein kinase C (PKC) and link PKC to specific beta(1) integrins. J Biol Chem 276: 25005-25013
46. Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP (2008) The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 13: 221-234 (Pubitemid 351318371)